Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Jun 30;14(6):3272-3276.
doi: 10.21037/tcr-2025-263. Epub 2025 Jun 18.

ROS1 fusion-positive non-small cell lung cancer-repotrectinib as a new treatment option

Sacha I Rothschild  1   2 , Laetitia A Mauti  3
Affiliations
Editorial

ROS1 fusion-positive non-small cell lung cancer-repotrectinib as a new treatment option

Sacha I Rothschild et al. Transl Cancer Res. .
No abstract available

Keywords: ROS1; non-small cell lung cancer (NSCLC); repotrectinib; targeted therapy.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://tcr.amegroups.com/article/view/10.21037/tcr-2025-263/coif). S.I.R. reports consulting fees (payment to the institution) from Amgen, AstraZeneca, Bayer, BMS, Boehringer-Ingelheim, Eisai, Eli Lilly, Merck Serono, MSD, Novartis, Otsuka, Pfizer, PharmaMar, Roche Pharma, Roche Diagnostics, Sanofi Aventis, and Takeda; research support from Amgen, Astra-Zeneca, Merck, and Roche; honoraria for lectures, presentations (payment to the institution) from Amgen, AstraZeneca, BMS, MSD Oncology, Novartis, Roche Pharma, Roche Diagnostics, and Takeda; payment for expert testimony (payment to the institution) from AstraZeneca, BMS, Roche Pharma; support for travel and accommodations (payment to the institution) from Amgen, AstraZeneca, BMS, Eli Lilly, MSD, Roche, and Takeda; participation on Data Safety Monitoring Board (payment to the institution) from Roche; and being a member of the Federal Drug Commission of the Federal Office of Public Health. L.A.M. reports consulting fees from Amgen, AstraZeneca, BMS, Merck, MSD, Novartis, Pfizer, Roche Pharma, Regeneron, Janssen, and Daichii-Sankyo; research support from AstraZeneca, and Gilead; honoraria for lectures, presentations from Merck, AstraZeneca; payment for expert testimony from BMS; and support for travel and accommodations from Sanofi, AstraZeneca, and Roche. The authors have no other conflicts of interest to declare.

Comment on

  • Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer.
    Drilon A, Camidge DR, Lin JJ, Kim SW, Solomon BJ, Dziadziuszko R, Besse B, Goto K, de Langen AJ, Wolf J, Lee KH, Popat S, Springfeld C, Nagasaka M, Felip E, Yang N, Velcheti V, Lu S, Kao S, Dooms C, Krebs MG, Yao W, Beg MS, Hu X, Moro-Sibilot D, Cheema P, Stopatschinskaja S, Mehta M, Trone D, Graber A, Sims G, Yuan Y, Cho BC; TRIDENT-1 Investigators. Drilon A, et al. N Engl J Med. 2024 Jan 11;390(2):118-131. doi: 10.1056/NEJMoa2302299. N Engl J Med. 2024. PMID: 38197815 Free PMC article. Clinical Trial.

References

    1. Matsushime H, Wang LH, Shibuya M. Human c-ros-1 gene homologous to the v-ros sequence of UR2 sarcoma virus encodes for a transmembrane receptorlike molecule. Mol Cell Biol 1986;6:3000-4. - PMC - PubMed
    1. Birchmeier C, Birnbaum D, Waitches G, et al. Characterization of an activated human ros gene. Mol Cell Biol 1986;6:3109-16. - PMC - PubMed
    1. Rikova K, Guo A, Zeng Q, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 2007;131:1190-203. 10.1016/j.cell.2007.11.025 - DOI - PubMed
    1. Shaw AT, Ou SH, Bang YJ, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med 2014;371:1963-71. 10.1056/NEJMoa1406766 - DOI - PMC - PubMed
    1. Drilon A, Siena S, Dziadziuszko R, et al. Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials. Lancet Oncol 2020;21:261-70. 10.1016/S1470-2045(19)30690-4 - DOI - PMC - PubMed

LinkOut - more resources